financetom
Business
financetom
/
Business
/
Dominion beats quarterly estimates on Virginia, South Carolina power demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dominion beats quarterly estimates on Virginia, South Carolina power demand
May 25, 2025 11:17 PM

May 1 (Reuters) -

U.S. utility Dominion Energy ( D ) reported first-quarter

revenue and profit above Wall Street expectations on Thursday,

helped by lower interest costs and strong demand from Virginia

and South Carolina.

Power demand in the U.S. is expected to hit record highs in

2025 and 2026, driven by demand from data centers for artificial

intelligence and cryptocurrency technologies and from homes and

businesses for heat and transportation, according to the U.S.

Energy Information Administration.

Adjusted operating earnings from Dominion's Virginia segment

rose 32.3% to $561 million in the first quarter, and that from

the South Carolina segment rose 90% to $152 million.

Dominion's Virginia utility services the world's largest

cluster of data centers, which has a bigger capacity than the

next four largest global data center clusters combined,

according to the company.

Dominion Energy ( D ) also said its interest expenses fell 16.4%

to $480 million in the first-quarter.

Lower interest rates reduce borrowing costs for power

companies, which usually need higher capital to maintain and

upgrade grid infrastructure.

Dominion's electric and gas service areas saw a 25.6%

rise in actual heating degree days - a measure of energy demand

for space heating - in the quarter.

Quarterly revenue was $4.08 billion, up from $3.63 billion a

year ago, beating analysts' estimate of $3.97 billion, according

to data compiled by LSEG.

The company reaffirmed its annual adjusted operating

earnings forecast of between $3.28 per share and $3.52 per

share; analysts have estimated $3.39 per share.

The utility's adjusted operating earnings was 93 cents per

share for the three months ended March 31, compared with

analysts' average estimate of 75 cents per share, according to

data compiled by LSEG.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AtkinsRealis
AtkinsRealis "Well-positioned" to Capture New Build Nuclear Opportunities, Says BMO
Nov 14, 2025
02:06 PM EST, 11/14/2025 (MT Newswires) -- AtkinsRealis Group's ( SNCAF ) nuclear business continues to outpace expectations and appears well-positioned to capture new build opportunities over the intermediate-to-long term, notes BMO. Even though the Engineering Services business experienced some challenges in 2025, growth is still expected to re-accelerate in the coming quarters, writes analyst Devin Dodge. Layering in a...
Cosa Resources Upsizing Private Placement to $7.5 Million
Cosa Resources Upsizing Private Placement to $7.5 Million
Nov 14, 2025
02:10 PM EST, 11/14/2025 (MT Newswires) -- Cosa Resources ( COSAF ) on Friday upsized a commercially reasonable efforts private-placement offering to $7.5 million, up from its prior $5-million target. The offering now consists of the issuance of up to 11.5-million hard dollar units at $0.26 apiece, up to 7.5-million charity flow-through units at $0.398 per Charity FT unit, and...
Oracle bonds sell off as AI investment fuels investor concerns
Oracle bonds sell off as AI investment fuels investor concerns
Nov 14, 2025
Nov 14 (Reuters) - Oracle Corp ( ORCL ) bonds have taken a hit in recent days following a report that the cloud and artificial intelligence service provider plans to add another $38 billion to its heavy debt load to fund its AI infrastructure, according to analysts and investors. Oracle did not immediately respond to a request for comment. Oracle...
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries
Nov 14, 2025
Nov 14 (Reuters) - The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' ( SRPT ) gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients 4 years of age and older with Duchenne muscular dystrophy. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved